A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Registration Number
- NCT06208150
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 795
- Documented multiple myeloma as defined by the criteria below: (a) multiple myeloma diagnosis according to the international myeloma working group (IMWG) diagnostic criteria (b) measurable disease at screening as assessed by central laboratory, defined by any of the following: (i) serum M-protein level greater than or equal to (>=) 0.5 gram per deciliter (g/dL); or (ii) urine M-protein level >= 200 milligram (mg) per 24 hours; or (iii) light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- Relapsed or refractory disease as defined below: a) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by IMWG criteria greater than (>) 60 days after cessation of treatment. b) Refractory disease is defined as less than (<) 25 percent (%) reduction in M-protein or confirmed PD by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Documented evidence of PD or failure to achieve a minimal response to the last line of therapy based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
- A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6months after the last dose of study treatment
- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients
- Stroke, transient ischemic attack, or seizure within 6 months prior to signing informed consent form (ICF)
- Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment
- A maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14-day period before the first dose of study drug
- Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Talquetamab + Pomalidomide (Tal-P) Talquetamab Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm A: Talquetamab + Pomalidomide (Tal-P) Pomalidomide Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm A: Talquetamab + Pomalidomide (Tal-P) Dexamethasone Participants will receive talquetamab as subcutaneous (SC) injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm B: Talquetamab + Teclistamab (Tal-Tec) Talquetamab Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm B: Talquetamab + Teclistamab (Tal-Tec) Dexamethasone Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm B: Talquetamab + Teclistamab (Tal-Tec) Teclistamab Participants will receive teclistamab in combination with talquetamab both as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) Pomalidomide Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication. Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) Elotuzumab Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication. Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) Dexamethasone Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication. Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) Bortezomib Participants will either receive elotuzumab intravenous (IV) injection in combination with pomalidomide and dexamethasone orally; or pomalidamide orally in combination with bortezomib SC injection and dexamethasone orally as per investigator choice. Dexamethasone will be administered as a pretreatment medication.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) Up to 6 years 5 months PFS is defined as the duration from the date of randomization to either progressive disease or death, whichever comes first.
- Secondary Outcome Measures
Name Time Method Overall Response Rate (ORR) Up to 6 years 5 months ORR is defined as the percentage of participants with best overall response of partial response (PR) or better according to international myeloma working group (IMWG) response criteria.
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Up to 6 years 5 months Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The MySIm-Q is a disease-specific patient-reported outcome (PRO) assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30). It includes 17 items resulting in a symptom subscale and an impact subscale.
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L) Up to 6 years 5 months Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Epstein Taste Survey Up to 6 years 5 months Change from baseline in symptoms, functioning, and HRQoL as assessed by epstein taste survey will be reported. The epstein taste survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes. developed for use in patients with head and neck cancer as a composite of the Vanderbilt Head and Neck Symptom Survey.
Complete Response (CR) or Better Rate Up to 6 years 5 months CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria.
Minimal Residual Disease (MRD)-negative CR Rate Up to 6 years 5 months MRD-negative CR is defined as the percentage of participants who achieve both CR or better and MRD negativity at a threshold of 10\^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy (SST).
Overall Survival (OS) Up to 6 years 5 months OS is defined as the time from randomization to the date of participant's death.
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EORTC-QLQ-C30 Up to 6 years 5 months Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea or vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level.
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Epstein Taste Survey Up to 6 years 5 months Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The epstein taste survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes developed for use in patients with head and neck cancer as a composite of the Vanderbilt Head and Neck Symptom Survey.
Very Good Partial Response (VGPR) or Better Rate Up to 6 years 5 months VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria.
Number of Participants with Anti-drug Antibodies (ADAs) to Talquetamab and Teclistamab Up to 6 years 5 months Number of participants with ADAs to talquetamab and teclistamab will be reported.
Time to Sustained Worsening in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Patient Global Impression -Severity (PGI-S) Up to 6 years 5 months Time to sustained worsening in symptoms, functioning and HRQoL is defined as the interval from the date of randomization to the start date of meaningful change. The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and EORTC-QLQ-C30 in this population. The response options are presented as a 5-point verbal rating scale from "none" to "very severe."
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by MySIm-Q Up to 6 years 5 months Change from baseline in symptoms, functioning, and HRQoL as assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific patient-reported outcome (PRO) assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30). It includes 17 items resulting in a symptom subscale and an impact subscale.
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EORTC-QLQ-C30 Up to 6 years 5 months Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea or vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high or healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale or item represents a high level of symptomatology or problems.
Percentage of Participants With Meaningful Improvement in HRQoL as Assessed by EORTC-QLQ-C30 Up to 6 years 5 months Percentage of participants with meaningful improvement in HRQol as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea or vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days ("past week"), and responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high or healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale or item represents a high level of symptomatology or problems.
Progression Free Survival on Next-line Therapy (PFS2) Up to 6 years 5 months PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first.
Time to Next Treatment (TTNT) Up to 6 years 5 months TTNT is defined as the time from randomization to the start of SST.
Serum Concentration of Talquetamab and Teclistamab Up to 6 years 5 months Serum concentration of talquetamab and teclistamab will be reported.
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by EQ-5D-5L Up to 6 years 5 months Change from baseline in symptoms, functioning, and HRQoL as assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by PGI-S Up to 6 years 5 months Change from baseline in symptoms, functioning, and HRQoL as assessed by PGI-S will be reported. The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and EORTC-QLQ-C30 in this population. The response options are presented as a 5-point verbal rating scale from "none" to "very severe."
Trial Locations
- Locations (231)
Akademiska Sjukhuset
🇸🇪Uppsala, Sweden
Varberg Hospital
🇸🇪Varberg, Sweden
UCSF Fresno
🇺🇸Clovis, California, United States
UCLA
🇺🇸Santa Monica, California, United States
Yale University School Of Medicine
🇺🇸New Haven, Connecticut, United States
Medical Oncology Hematology Consultants, PA
🇺🇸Newark, Delaware, United States
Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Winship Cancer Institute Emory University
🇺🇸Atlanta, Georgia, United States
Kootenai Health
🇺🇸Coeur d'Alene, Idaho, United States
University of Iowa Health Care
🇺🇸Waukee, Iowa, United States
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Luminis Health Center for Cancer and Blood Disorders
🇺🇸Annapolis, Maryland, United States
University of Maryland School of Medicine
🇺🇸Baltimore, Maryland, United States
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins
🇺🇸Baltimore, Maryland, United States
University of Michigan
🇺🇸Ann Arbor, Michigan, United States
Henry Ford Cancer Institute
🇺🇸Detroit, Michigan, United States
Ascension Providence Hospital
🇺🇸Southfield, Michigan, United States
University Of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Regions Hospital
🇺🇸Saint Paul, Minnesota, United States
University of Nebraska
🇺🇸Omaha, Nebraska, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Weill Cornell Medical College
🇺🇸New York, New York, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Louis Stokes Cleveland VA Med Ctr
🇺🇸Cleveland, Ohio, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Oregon Health And Science University
🇺🇸Portland, Oregon, United States
Penn State Milton S Hershey Medical Ctr
🇺🇸Hershey, Pennsylvania, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
West Penn Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
Bon Secours Saint Francis Cancer Center
🇺🇸Greenville, South Carolina, United States
UT Southwestern
🇺🇸Dallas, Texas, United States
Houston Methodist Neal Cancer Center at Texas Medical Center
🇺🇸Houston, Texas, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Fred Hutchinson Cancer Research Center
🇺🇸Seattle, Washington, United States
NorthWest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
Gundersen Health System
🇺🇸La Crosse, Wisconsin, United States
Medical College Of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Fundaleu
🇦🇷Buenos Aires, Argentina
Hospital Aleman
🇦🇷Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Royal Adelaide Hospital
🇦🇺Adelaide, Australia
Box Hill Hospital
🇦🇺Box Hill, Australia
St Vincents Hospital
🇦🇺Darlinghurst, Australia
St Vincents Hospital Melbourne
🇦🇺Fitzroy, Australia
Gold Coast University Hospital
🇦🇺Southport, Australia
Perth Blood Institute
🇦🇺West Perth, Australia
Wollongong Hospital
🇦🇺Wollongong, Australia
LKH - Universitätsklinikum der PMU Salzburg
🇦🇹Salzburg, Austria
Klinik Ottakring
🇦🇹Vienna, Austria
Medical University Vienna MUV
🇦🇹Vienna, Austria
Grand Hopital De Charleroi Site Les Viviers
🇧🇪Charleroi, Belgium
Ziekenhuis Oost-Limburg
🇧🇪Genk, Belgium
Ghent University Hospital
🇧🇪Gent, Belgium
AZ Nikolaas - Campus Sint-Niklaas Moerland
🇧🇪Sint-Niklaas, Belgium
Cetus Oncologia
🇧🇷Belo Horizonte, Brazil
DF Star
🇧🇷Brasilia, Brazil
Fundacao Universidade de Caxias do Sul
🇧🇷Caxias do Sul, Brazil
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Hospital De Clinicas De Porto Alegre
🇧🇷Porto Alegre, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Recife, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
🇧🇷Rio de Janeiro, Brazil
Hospital Sao Rafael
🇧🇷Salvador, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
🇧🇷Sao Jose do Rio Preto, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Clinica Medica Sao Germano S/S LTDA
🇧🇷Sao Paulo, Brazil
Instituto D Or de Pesquisa e Ensino
🇧🇷Sao Paulo, Brazil
Arthur J E Child Comprehensive Cancer Centre
🇨🇦Calgary, Alberta, Canada
British Columbia Cancer Agency
🇨🇦Vancouver, British Columbia, Canada
Nova Scotia Health Authority
🇨🇦Halifax, Nova Scotia, Canada
Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
Princess Margaret Cancer Centre University Health Network
🇨🇦Toronto, Ontario, Canada
CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
🇨🇦Montreal, Quebec, Canada
Saskatoon Cancer Centre
🇨🇦Saskatoon, Saskatchewan, Canada
Beijing Chaoyang Hospital
🇨🇳Beijing, China
Peking University First Hospital
🇨🇳Beijing, China
Peking University People s Hospital
🇨🇳Beijing, China
The Second Xiangya Hospital of Central South Hospital
🇨🇳Changsha, China
Changzhou No 2 Peoples Hospital
🇨🇳Changzhou, China
Sichuan Provincial Peoples Hospital
🇨🇳Chengdu, China
Fujian Meidical University Union Hospital
🇨🇳Fuzhou, China
Sun Yat Sen University Cancer Center
🇨🇳Guangzhou, China
Nanfang Hospital of Southern Medical Hospital
🇨🇳Guangzhou, China
First hospital affiliated of Zhejiang Medical university
🇨🇳Hangzhou, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
🇨🇳Hangzhou, China
The Affiliated Hospital of Inner Mongolia Medical College
🇨🇳Hu He Hao Te Shi, China
Qilu Hospital of Shandong University
🇨🇳Jinan, China
The First Affiliated Hospital of Guangxi Medical University
🇨🇳Nan Ning Shi, China
The First Affiliated Hospital of NanChang University
🇨🇳Nanchang, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
🇨🇳Shanghai, China
Tongji Hospital of Tongji University
🇨🇳Shanghai, China
Shanghai Fourth People s Hospital
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, China
Shanxi Bethune Hospital
🇨🇳Tai Yuan Shi, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, China
Tongji Hospital, Tongji Medical College of HUST
🇨🇳Wuhan, China
The Second Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, China
Fakultni nemocnice Brno
🇨🇿Brno - Bohunice, Czechia
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
University Hospital Olomouc
🇨🇿Olomouc, Czechia
Fakultni Nemocnice Ostrava
🇨🇿Ostrava, Czechia
Aarhus University Hospital
🇩🇰Aarhus, Denmark
Odense University Hospital
🇩🇰Odense C, Denmark
Vejle Hospital
🇩🇰Vejle, Denmark
Hopital Claude Huriez
🇫🇷Lille, France
CHU de Limoges Hopital Dupuytren
🇫🇷Limoges, France
Institut Paoli Calmettes
🇫🇷Marseille, France
CHU Nantes
🇫🇷Nantes, France
Hopital Saint Louis
🇫🇷Paris, France
CHU de Bordeaux - Hospital Haut-Leveque
🇫🇷Pessac Cedex, France
CHU Lyon Sud
🇫🇷Pierre Benite, France
Institut de Cancerologie Strasbourg Europe ICANS
🇫🇷Strasbourg, France
Institut Universitaire du Cancer Toulouse Oncopole
🇫🇷Toulouse Cedex 9, France
CHRU Tours Hopital Bretonneau
🇫🇷TOURS Cedex 01, France
Klinikum Augsburg
🇩🇪Augsburg, Germany
Universitaetsklinikum Halle Saale
🇩🇪Halle (Saale), Germany
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitaetsklinikum Magdeburg A.oe.R
🇩🇪Magdeburg, Germany
Klinikum rechts der Isar der TU Muenchen
🇩🇪München, Germany
Universitaetsklinikum Tuebingen
🇩🇪Tuebingen, Germany
Universitaetsklinikum Wuerzburg
🇩🇪Würzburg, Germany
251 Airforces Hospital
🇬🇷Athens, Greece
Alexandra General Hospital of Athens
🇬🇷Athens, Greece
Anticancer Hospital of Thessaloniki Theageneio
🇬🇷Thessaloniki, Greece
Semmelweis Egyetem, Belgyogyaszati es Hematologiai Klinika
🇭🇺Budapest, Hungary
Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
🇭🇺Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz
🇭🇺Nyiregyhaza, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont
🇭🇺Pecs, Hungary
Fortis Memorial Research Institute
🇮🇳Gurgaon, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences
🇮🇳Lucknow, India
Deenanath Mangeshkar Hospital and Research Centre
🇮🇳Pune, India
Shamir Medical Center Assaf Harofeh
🇮🇱Be'er Ya'akov, Israel
Carmel Medical Center
🇮🇱Haifa, Israel
Rabin Medical center - Petah-Tikva
🇮🇱Petah-Tikva, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv-Yafo, Israel
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
🇮🇹Alessandria, Italy
A O U Sant Orsola Malpighi
🇮🇹Bologna, Italy
oncologia medica - Oncology
🇮🇹Brindisi, Italy
ARNAS Garibaldi P O Nesima
🇮🇹Catania, Italy
Ospedale Policlinico San Martino IRCCS
🇮🇹Genova, Italy
Asst Ovest Milanese - Ospedale Di Legnano
🇮🇹Legnano, Italy
Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano
🇮🇹Milano, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milano, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
Presidio Ospedaliero Pescara
🇮🇹Pescara, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
Oncologia Medica-Città Della Salute E Della Scienza Di Torino
🇮🇹Torino, Italy
Azienda Ospedaliera Universitaria Integrata Verona
🇮🇹Verona, Italy
Juntendo University Hospital
🇯🇵Bunkyo Ku, Japan
Fukuoka University Hospital
🇯🇵Fukuoka, Japan
Hamamatsu University Hospital
🇯🇵Hamamatsu, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Japan
University Hospital Kyoto Prefectural University of Medicine
🇯🇵Kyoto, Japan
National Hospital Organization Nagasaki Medical Center
🇯🇵Nagasaki, Japan
Japanese Red Cross Narita Hospital
🇯🇵Narita, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Hyogo Medical University Hospital
🇯🇵Nishinomiya shi, Japan
Japanese Red Cross Osaka Hospital
🇯🇵Osaka, Japan
Sapporo City General Hospital
🇯🇵Sapporo, Japan
Tohoku University Hospital
🇯🇵Sendai, Japan
Japanese Red Cross Medical Center
🇯🇵Shibuya-ku, Japan
Iwate Medical University Hospital
🇯🇵Shiwa-gun, Japan
The University of Osaka Hospital
🇯🇵Suita City, Japan
Shizuoka Cancer Center
🇯🇵Sunto Gun, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Tottori University Hospital
🇯🇵Tottori, Japan
University of Tsukuba Hospital
🇯🇵Tsukuba, Japan
Kanagawa Cancer Center
🇯🇵Yokohama City, Japan
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Ulsan University Hospital
🇰🇷Ulsan, Korea, Republic of
Centro de Quimioterapia e Investigacion
🇲🇽Guadalajara, Mexico
Hematologica Alta Especialidad
🇲🇽Huixquilucan, Mexico
Hospital Universitario Dr Jose Eleuterio Gonzalez
🇲🇽Monterrey, Mexico
Flevoziekenhuis
🇳🇱Almere, Netherlands
Haga ziekenhuis
🇳🇱Den Haag, Netherlands
Catharinaziekenhuis
🇳🇱Eindhoven, Netherlands
St. Antonius Ziekenhuis Nieuwegein
🇳🇱Nieuwegein, Netherlands
Isala Kliniek
🇳🇱Zwolle, Netherlands
Wojewodzki Szpital Specjalistyczny
🇵🇱Biala Podlaska, Poland
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
🇵🇱Brzozow, Poland
Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
🇵🇱Kielce, Poland
Centrum Onkologii Ziemii Lubelskiej
🇵🇱Lublin, Poland
Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
🇵🇱Szczecin, Poland
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
🇵🇱Wroclaw, Poland
King Abdullah International Medical Research Center (KAIMRC)
🇸🇦Riyadh, Saudi Arabia
King Faisal Specialist Hospital & Research Center
🇸🇦Riyadh, Saudi Arabia
King Fahad Medical City
🇸🇦Riyadh, Saudi Arabia
Hosp. de Cabuenes
🇪🇸Asturias, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. Univ. de Burgos
🇪🇸Burgos, Spain
Hosp. San Pedro de Alcantara
🇪🇸Cáceres, Spain
Hosp. Univ. Virgen de Las Nieves
🇪🇸Granada, Spain
Hosp. Univ. Lucus Augusti
🇪🇸Lugo, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp. Univ. Son Espases
🇪🇸Palma de Mallorca, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Complejo Hosp de Navarra - Hosp de Navarra
🇪🇸Pamplona, Spain
Hosp Clinico Univ de Salamanca
🇪🇸Salamanca, Spain
Hosp. Univ. Donostia
🇪🇸San Sebastian, Spain
Hosp. Univ. Marques de Valdecilla
🇪🇸Santander, Spain
Hosp. Clinico Univ. de Santiago
🇪🇸Santiago de Compostela, Spain
Skanes universitetssjukhus
🇸🇪Lund, Sweden
Norrlands Universitetssjukhus
🇸🇪Umea, Sweden
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
Liv Hospital Ankara
🇹🇷Ankara, Turkey
Pamukkale University Medical Faculty
🇹🇷Denizli, Turkey
Medipol University Hospital
🇹🇷Istanbul, Turkey
Ondokuz Mayis University
🇹🇷Samsun, Turkey
Blackpool Victoria Hospital
🇬🇧Blackpool, United Kingdom
University Hospital of Wales
🇬🇧Cardiff, United Kingdom
Ninewells Hospital
🇬🇧Dundee, United Kingdom
St James University Hospital
🇬🇧Leeds, United Kingdom
Kings College Hospital
🇬🇧London, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
University Hospitals Plymouth NHS Trust
🇬🇧Plymouth, United Kingdom
Queen Alexandra Hospital
🇬🇧Portsmouth, United Kingdom